Altitude pill may also fight inflammation, early study hints

NCT ID NCT07517068

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether acetazolamide, a drug already used for altitude sickness, can reduce inflammation and immune system activation caused by high altitude. Nineteen healthy adults will take either the drug or a placebo before and during a stay at 3800 meters. Researchers will measure changes in immune cells and inflammatory markers in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Acetazolamide

What this could lead to

If successful, this could help explain how acetazolamide prevents altitude sickness and may point to new ways to control inflammation.

What could go wrong

This is a very small, early-phase study (19 people) looking at blood markers, not symptoms. Results may not apply to the general public or lead to a treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOXEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute mountain sickness altitude sickness Hypoxia Inflammation inflammatory disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of California, Riverside

    Riverside, California, 92521, United States